PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars

BACKGROUND: With the introduction of tumor necrosis factor (TNF) alpha inhibitors, the treatment of inflammatory rheumatic diseases (IRD) has undergone a fundamental change. Several of the originally high-priced biologics are now accessible as lower cost biosimilars, removing a significant impedimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hörbrand, Franziska, Schuch, Florian, Bleß, Hans-Holger, Messinger, David, Bretthauer, Bork, Killian, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2022
Materias:
Versorgung
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627965/
https://www.ncbi.nlm.nih.gov/pubmed/36006471
http://dx.doi.org/10.1007/s00393-022-01259-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627965/
https://www.ncbi.nlm.nih.gov/pubmed/36006471
http://dx.doi.org/10.1007/s00393-022-01259-5

Ejemplares similares